|
[SuperNK] Safety and efficacy of SNK01 in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer (J Immunother Cancer. 2024) |
|
|
[NK Vue] The role of natural killer cell activity as a milestone in oncologic outcome after curative resection of pancreatic adenocarcinoma (J Surg Oncol. 2023) |
|
|
[Murine NK Cell Activity Kit] Green synthesis of oncolytic Newcastle disease virus-loaded thiolated chitosan nanoformulation for CD44 targeted delivery and sustained release of virus in cervical cancer xenografts (Cancer Nanotechnol. 2023) |
|
|
[NK Vue] Low Muscle and High Fat Percentages Are Associated with Low Natural Killer Cell Activity: A Cross-Sectional Study (Int. J. Mol. Sci. 2023) |
|
|
[NK Vue] Relationship between Serum Cortisol, Dehydroepiandrosterone Sulfate (DHEAS) Levels, and Natural Killer Cell Activity: A Cross-Sectional Study (J. Clin. Med. 2023) |
|
|
[NK Vue] NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors (Br J Cancer. 2023) |
|
|
[SuperNK] Two-year efficacy of SNK01 plus pembrolizumab for non-small cell lung cancer: Expanded observations from a phase I/IIa randomized controlled trial (Thorac Cancer. 2022) |
|
|
[NK Vue] Preliminary Study on Natural Killer Cell Activity for Interferon-Gamma Production after Gamma Knife Radiosurgery for Brain Tumors (J Korean Neurosurg Soc. 2022) |
|
|
[NK Vue] Natural killer cell activity as a biomarker for the diagnosis of lung cancer in high-risk patients (J Int Med Res. 2022) |
|
|
[NK Vue] A Case-Control Study on the Changes in Natural Killer Cell Activity following Administration of Polyvalent Mechanical Bacterial Lysate in Korean Adults with Recurrent Respiratory Tract Infection (J. Clin. Med. 2022) |
|
|
[NK Vue] Cross-Sectional and Time-Dependent Analyses on Inflammatory Markers following Natural Killer Cell Activity. (Diagnostics. 2022) |
|
|
[NK Vue] Prognostic value of natural killer cell activity for patients with HER2+ advanced gastric cancer treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab. (Cancer Immunol Immunother. 2021) |
|
|
[NK Vue] Changes in natural killer cell activity after surgery and predictors of its recovery-failure. (J Surg Oncol. 2021) |
|
|
[SuperNK] A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer (Cancer Res Treat. 2022) |
|
|
[Murine NK Cell Activity Kit] Immune-Enhancing Effects of Lactobacillus plantarum 200655 Isolated from Korean Kimchi in a Cyclophosphamide-Induced Immunocompromised Mouse Model (J Microbiol Biotechnol. 2021) |
|